Technology

Analyzing protein biomarker signatures in urine samples to detect cancer

Our diagnostic technology is based on: 

•   Noninvasive liquid biopsies using urine

•   Proprietary set of cancer biomarkers

•   Protein expression classifier

The goal of liquid biopsies is to move the standard of care away from subpar, outdated urine tests to a modern, accurate urinalysis.

Nonagen Bioscience’s work is based on a proprietary set of 10 cancer biomarkers characterized, in part, by expression patterns in human bladder cancer. Discovered within the laboratories of Dr. Goodison and Dr. Rosser, the biomarkers were validated through extensive research and collaborative agreements with numerous first-rate international research institutes. 

These 10 proteins regulate such diverse processes as cell proliferation, cell migration, and blood vessel formation. Many of these proteins have not been previously associated with bladder cancer. 

Using a proprietary algorithm called a multivariate classifier (risk calculator) within a HIPAA-compliant cloud-based storage service, the protein and clinical data are extensively and securely analyzed. The risk calculator associated with the multiplex protein Oncuria® test produces a customized report within minutes. 

This report identifies the probability of the patient harboring bladder cancer and can assist healthcare providers with the counseling and care of each patient.

The OncuriA White Paper

Learn how the Oncuria multiplex immunoassay was developed and how it compares to existing urine-based tests for bladder cancer.

Download Now